SLC5A2 and atherosclerosis: Specifically, the risk of MACE and (fatal and nonfatal) MI, respectively, were shown to be significantly reduced by SGLT2 inhibitors only in type 2 diabetic patients with established ASCVD, but not in those without ASCVD39,40.